

## ANNUAL DECLARATION OF INTERESTS (ADoI)

(Please note that high quality of scientific expertise is by nature based on prior experience and that therefore having an interest does not necessarily mean having a conflict of interest)

Name: FOWLER, Paul

Title: Prof.

**Profession:** Professor

Current EFSA involvements: Member-CEF Panel 2014-2017 (CEF), Member-Flavourings WG 2014-2017 (CEF)

| Nature of Activities                                    | Period | Organisation | Subject matter |
|---|--------|--------------|----------------|
| I. Economic interest                                    |        |              | NO INTEREST    |
| II. Member of a managing entity or equivalent structure |        |              | NO INTEREST    |
| III. Member of a scientific advisory entity             |        |              | NO INTEREST    |

| IV. Employment            | 02/1986 - now     | -Name: University of Aberdeen,<br>Scottish Funding Council                                      | For the last 5 years my research has focused on the effects of environmental and recreational chemicals on fetal development, health and reproductive function in humans and animals species, predominantly sheep and mice.  Current post: August 2008 – Tenured Professor (Chair in Translational Medical Sciences), Division Applied Medicine, University of Aberdeen. SFC-funded, termination date 30.09.2024.  My research has NOT specifically included studies of BPA by my own group. |
|---------------------------|-------------------|---|--|
| V. Occasional consultancy | 11/2014 - now     | -Name: Agence d'Evaluation de la<br>Recherche et de l'Enseignement<br>Supérieur (AERES), FRANCE | Assessment of research institutes and universities, confidential. Appointments are ad hoc, this is my second since 2013.   |
|                           | 01/2010 - 12/2010 | -Name: Swedish Research Council   | Member, Standing Evaluation Panel, Environmental Pollution at the Swedish Research Council Formas. This involved evaluating grant applications, including applications with direct analysis of BPA. However, only evaluated the projects, I played no role in the projects themselves, if funded.  |
| VI. Research funding      | 03/2014 - now     | -Name: Medical Research Council   | The human fetal liver: development and response to maternal drug use.  |
|                           | 01/2014 - now     | -Name: Society for Reproduction<br>& Fertility  | Does exposure to a complex cocktail of environmental chemicals during pregnancy and lactation alter metabolic and steroid hormone systems in the adult liver?  |
|                           | 10/2013 - now     | -Name: Wellcome TRust   | Prenatal programming of adult disease by maternal smoking: the adrenal gland as a key player?  |
|                           | 01/2010 - 12/2011 | -Name: CSO  | Bioincubator system to model toxic effects on the human fetal testis.  |
|                           |                   |   | This project did not include specific analysis of BPA.   |
|                           | 05/2009 - 10/2011 | -Name: EC   | Investigation of effects of environmental chemicals in animal (sheep and mice) and human development and function, particularly in terms of reproduction.  |
|                           |                   |   | This work did not include any analysis of BPA.   |
|                           | 05/2010 - 08/2010 | -Name: Holly Hill Trust   | The effects of in utero exposure to di(2-ethylhexyl) phthalate (DEHP) and polychlorinated biphenyls via maternal ingestion on the foetal sheep ovary.  |
|                           |                   |   | This project did not include specific analysis of BPA.   |
|                           | 05/2007 - 04/2010 | -Name: Wellcome Trust   | Effect of in-utero exposure to environmental chemicals via maternal pasture ingestion on fetal development.  |
|                           |                   |   | This work did not include specific analysis of BPA.  |
|                           | 04/2009 - 03/2010 | -Name: NHS Grampiian  | Fetal human gonadal cannabinoid receptors: expression and effects of maternal smoking.   |
|                           |                   |   | This project did not include the specific analysis of BPA.   |
|                           | 04/2008 - 03/2009 | -Name: NHS Grampian   | Does maternal smoking disrupt key developmental sex steroid hormones in the fetus?   |
|                           |                   |   | This project did not include specific analysis of BPA.   |

| VII. Intellectual property rights VIII. Other memberships or affiliations | 05/2007 - 04/2008<br>07/2009 - now | -Name: NHS R&D  -Name: Society for Reproduction & Fertility | Salary supplement for Wellcome project "Effect of in-utero exposure to environmental chemicals via maternal pasture ingestion on fetal development."  This work did not include specify analyses of BPA.  NO INTEREST  This is a research charity and was the chair of the council of management 2009-2013. Any small projects funded by this charity,   |
|---|------------------------------------|---|--|
|   |                                    |   | which may have included BPA, are decided by a committee that is independent of me and I have played no role in any such project involving BPA. I now serve on the Programme Committee  |
| IX. Other relevant interest   | 11/2014 - now                      | -Name: Molecular & Cellular<br>Endocrinology                | I am a member of this Editorial Board  |
|   | 04/2014 - now                      | -Name: European Commission<br>Research Executive Agency     | Expert evaluator of applications for Horizon 2020. At present I have NOT been asked to evaluate any applications and this is likely in part because I am a partner in 3 applications currently being considered by Horizon 2020. These are as follows:   |
|   |                                    |   | Partner in two Horizon 2020 research grant applications currently under consideration:   |
|   |                                    |   | 1. Placental "omics" Diagnostic tools for exposure and disease prevention (PLACENTOMICS), €6 million. 7 partners (Finland, Czech, Spain, Belgium (x2), Austria, UK). Aberdeen share €1 million. 2. Innovation in Predictive Risk Assessment of Complex Mixtures of Mycotoxins and Persistent Organic Pollutants (PREDICTMIX), €8 million. 7 partners (Norway (x3), France, UK (x2), Germany). Aberdeen share €1 million. |
|   |                                    |   | Work-package leader in one Horizon 2020 MSCA ITN:  |
|   |                                    |   | 1. Endocrine disruptors; detection, mixtures, health effects, risk assessment and education (PROTECTEd), 8 academic/research institute partners (UK (x2), Norway (x3), Belgium, France, Chile) and 3 SMEs (UK, Netherlands, Belgium). Project designed for 15 ESRs.  |
|   | 03/2014 - now                      | -Name: Endocrine Society                                    | Economic costs of endocrine disrupting chemicals   |
|   | 03/2014 - now                      | -Name: European Commission<br>COST                          | Targeted Network Rapporteur. This is for "Gender, Science, Technology and Environment - genderSTE". Targeted Networks are policy-driven initiatives approved by the CSO under the COST Plan for Strategic Activities. My duties are to assess progress made by the project and whether it should be extended further.  |
|   | 01/2014 - now                      | -Name: Endocrinology  | I am a member of the editorial board of the journal "Endocrinology"  |
| X. Interests of close family members                                      |                                    |   | NO INTEREST  |

I hereby declare that I have read both the Guidance Document on Declarations of Interests and the Procedure for identifying and handling potential conflict of interests and that the above Declaration of Interests is complete.

Date: 19/11/2014 Signature: SIGNED